Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Neurological disorder diagnostic tools are those used in diagnosis of various neurological disorders. Neurological disorders can be diagnosed with the use of imaging and in vitro diagnostics techniques. Imaging techniques such as Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are used to create detailed images of organs, bones, soft tissue, blood vessels and different parts of body, while vitro diagnostic techniques consists of techniques such as biopsy, biomarker, blood test, urine test, and genetic testing.
Market Dynamics
Product launches and approvals of novel neurological diagnostic products is expected to be a major driver for growth of the global neurological disorder diagnostics. For instance, in 2016, Koninklijke Philips N.V. launched its latest Philips IQon Spectral CT in Canada. The latest Philips IQon Spectral CT is the world's first and only spectral detector CT, designed specifically for spectral imaging. With a new dual-layer spectral detector, the IQon Spectral CT has added spectral resolution to conventional CT scanning. Increasing research and development activities for development of novel diagnosis techniques for neurological disorder is also expected to fuel the market growth. For instance, in 2017, researchers from Assistance Publique - Hôpitaux de Paris (AP-HP) in collaboration with ICM researchers (Inserm/CNRS/UPMC) and Metafora Biosystems, developed a diagnostic blood test for De Vivo disease, a rare neurological illness. Increasing prevalence of neurological disorders is also expected to increase demand for diagnostic devices in the near future. For instance, According to World Alzheimer Report 2016, around 47 million people are living with dementia worldwide, and this is expected to increase about three-fold to reach 131 million by 2050. Alzheimer is one of the leading causes of dementia and accounts for an estimated 60% to 80% of all of dementia cases, according to 2018 Alzheimer's Facts and Figures published by Alzheimer's Association.
Key features of the study:
• This report provides in-depth analysis of neurological disorder diagnostics and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 - 2026), considering 2017 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
• It profiles leading players in the global neurological disorder diagnostics based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
• Key companies covered as a part of this study include Siemens Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation, York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global neurological disorder diagnostics report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the neurological disorder diagnostics
Detailed Segmentation:
• Global Neurological disorder diagnostics, By Technology :
o Imaging
o Computed Tomography (CT)
o Magnetic Resonance Imaging (MRI)
o Nuclear Medicine Imaging
o Positron Emission Tomography (PET)
o Single-Photon Emission Computed Tomography (SPECT)
o Near Infrared Spectroscopic Imaging (NIRS)
o Electroencephalography (EEG)
o Magnetoencephalography (MEG)
o In Vitro Diagnostics
o Biomarker
o Biopsy
o Others
• Global Neurological disorder diagnostics, By Disease Indication:
o Genetic Neurological Disorders
o Alzheimer's Disease (AD)
o Parkinson's Disease (PD)
o Amyotrophic Lateral Sclerosis (ALS)
o Huntington's Disease (HD)
o Others
o Immunological Neurological Disorders
o Multiple Sclerosis
o Others
o Paraneoplastic Syndrome
o Paraproteinemic neuropathies
o Others
• Global Neurological disorder diagnostics, By End User:
o Hospitals & Clinics
o Diagnostic Centers
o Ambulatory Care Centers
• Global Neurological disorder diagnostics, By Geography:
o North America
o Technology:
o Imaging
o Computed Tomography (CT)
o Magnetic Resonance Imaging (MRI)
o Nuclear Medicine Imaging
o Positron Emission Tomography (PET)
o Single-Photon Emission Computed Tomography (SPECT)
o Near Infrared Spectroscopic Imaging (NIRS)
o Electroencephalography (EEG)
o Magnetoencephalography (MEG)
o In Vitro Diagnostics
o Biomarker
o Biopsy
o Others
o By Disease Indication:
o Genetic Neurological Disorders
o Alzheimer's Disease (AD)
o Parkinson's Disease (PD)
o Amyotrophic Lateral Sclerosis (ALS)
o Huntington's Disease (HD)
o Others
o Immunological Neurological Disorders
o Multiple Sclerosis
o Others
o Paraneoplastic Syndrome
o Paraproteinemic neuropathies
o Others
o By End User
o Hospitals & Clinics
o Diagnostic Centers
o Ambulatory Care Centers
o By Country:
o U.S.
o Canada
o Europe
o Technology:
o Imaging
o Computed Tomography (CT)
o Magnetic Resonance Imaging (MRI)
o Nuclear Medicine Imaging
o Positron Emission Tomography (PET)
o Single-Photon Emission Computed Tomography (SPECT)
o Near Infrared Spectroscopic Imaging (NIRS)
o Electroencephalography (EEG)
o Magnetoencephalography (MEG)
o In Vitro Diagnostics
o Biomarker
o Biopsy
o Others
o By Disease Indication:
o Genetic Neurological Disorders
o Alzheimer's Disease (AD)
o Parkinson's Disease (PD)
o Amyotrophic Lateral Sclerosis (ALS)
o Huntington's Disease (HD)
o Others
o Immunological Neurological Disorders
o Multiple Sclerosis
o Others
o Paraneoplastic Syndrome
o Paraproteinemic neuropathies
o Others
o By End User
o Hospitals & Clinics
o Diagnostic Centers
o Ambulatory Care Centers
o By Country:
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
o Technology:
o Imaging
o Computed Tomography (CT)
o Magnetic Resonance Imaging (MRI)
o Nuclear Medicine Imaging
o Positron Emission Tomography (PET)
o Single-Photon Emission Computed Tomography (SPECT)
o Near Infrared Spectroscopic Imaging (NIRS)
o Electroencephalography (EEG)
o Magnetoencephalography (MEG)
o In Vitro Diagnostics
o Biomarker
o Biopsy
o Others
o By Disease Indication:
o Genetic Neurological Disorders
o Alzheimer's Disease (AD)
o Parkinson's Disease (PD)
o Amyotrophic Lateral Sclerosis (ALS)
o Huntington's Disease (HD)
o Others
o Immunological Neurological Disorders
o Multiple Sclerosis
o Others
o Paraneoplastic Syndrome
o Paraproteinemic neuropathies
o Others
o By End User
o Hospitals & Clinics
o Diagnostic Centers
o Ambulatory Care Centers
o By Country:
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Latin America
o Technology:
o Imaging
o Computed Tomography (CT)
o Magnetic Resonance Imaging (MRI)
o Nuclear Medicine Imaging
o Positron Emission Tomography (PET)
o Single-Photon Emission Computed Tomography (SPECT)
o Near Infrared Spectroscopic Imaging (NIRS)
o Electroencephalography (EEG)
o Magnetoencephalography (MEG)
o In Vitro Diagnostics
o Biomarker
o Biopsy
o Others
o By Disease Indication:
o Genetic Neurological Disorders
o Alzheimer's Disease (AD)
o Parkinson's Disease (PD)
o Amyotrophic Lateral Sclerosis (ALS)
o Huntington's Disease (HD)
o Others
o Immunological Neurological Disorders
o Multiple Sclerosis
o Others
o Paraneoplastic Syndrome
o Paraproteinemic neuropathies
o Others
o By End User
o Hospitals & Clinics
o Diagnostic Centers
o Ambulatory Care Centers
o By Country:
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Middle East
o Technology:
o Imaging
o Computed Tomography (CT)
o Magnetic Resonance Imaging (MRI)
o Nuclear Medicine Imaging
o Positron Emission Tomography (PET)
o Single-Photon Emission Computed Tomography (SPECT)
o Near Infrared Spectroscopic Imaging (NIRS)
o Electroencephalography (EEG)
o Magnetoencephalography (MEG)
o In Vitro Diagnostics
o Biomarker
o Biopsy
o Others
o By Disease Indication:
o Genetic Neurological Disorders
o Alzheimer's Disease (AD)
o Parkinson's Disease (PD)
o Amyotrophic Lateral Sclerosis (ALS)
o Huntington's Disease (HD)
o Others
o Immunological Neurological Disorders
o Multiple Sclerosis
o Others
o Paraneoplastic Syndrome
o Paraproteinemic neuropathies
o Others
o By End User
o Hospitals & Clinics
o Diagnostic Centers
o Ambulatory Care Centers
o By Country:
o GCC
o Israel
o Rest of Middle East
o Africa
o Technology:
o Imaging
o Computed Tomography (CT)
o Magnetic Resonance Imaging (MRI)
o Nuclear Medicine Imaging
o Positron Emission Tomography (PET)
o Single-Photon Emission Computed Tomography (SPECT)
o Near Infrared Spectroscopic Imaging (NIRS)
o Electroencephalography (EEG)
o Magnetoencephalography (MEG)
o In Vitro Diagnostics
o Biomarker
o Biopsy
o Others
o By Disease Indication:
o Genetic Neurological Disorders
o Alzheimer's Disease (AD)
o Parkinson's Disease (PD)
o Amyotrophic Lateral Sclerosis (ALS)
o Huntington's Disease (HD)
o Others
o Immunological Neurological Disorders
o Multiple Sclerosis
o Others
o Paraneoplastic Syndrome
o Paraproteinemic neuropathies
o Others
o By End User
o Hospitals & Clinics
o Diagnostic Centers
o Ambulatory Care Centers
o By Country:
o Central Africa
o South Africa
o North Africa
• Company Profiles
o Siemens Healthineers*
o Company Overview
o Product Portfolio
o Financial Performance
o Key Strategies
o Recent Developments
o Koninklijke Philips N.V.
o General Electric Company
o Esaote SpA
o NeuroLogica Corporation
o Masimo Corporation
o York Instruments Ltd.
o Neusoft Medical Systems
o Canon Medical Systems Corporation
"*" marked represents similar segmentation in other categories in the respective section.
